QuiaPEG

Newsroom

Feb 11, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today presented positive results from a preclinical study in the research project QPG-1029 (pegylated liraglutide), for the treatment of type 2 diabetes and overweight. The study evaluated the pharmacokinetic properties of QPG-1029 after intravenous and subcutaneous administration in rats.

Download press release (PDF)
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message